首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
【24h】

Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.

机译:不可切除的非小细胞肺癌患者中突变p53蛋白,P-糖蛋白和谷胱甘肽S-转移酶-pi的预后意义。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The prognostic significance of mutant p53 protein, p-glycoprotein (P-gp) and glutathione S-transferase-pi (GST-pi) in patients with unresectable non-small cell lung cancer (NSCLC) has not been established. MATERIALS AND METHODS: We performed immunohistochemical staining of p53, P-gp and GST-pi using transbronchial biopsy specimens obtained from previously untreated NSCLC patients. RESULTS: Of 45 patients examined, p53 immunostaining was positive in 18 (40%) patients. The objective response rate by cisplatin (CDDP)-based chemotherapy was significantly lower in patients with p53-positive tumors compared to those with p53-negative tumors (22% versus 59%, p = 0.0143). Survival of the patients with p53-positive tumors was significantly shorter than those with p53-negative tumors (median survival time: 4.6 months versus 12.2 months, p = 0.011), which was confirmed by the multivariate analysis (p = 0.0243). However, P-gp and GST-pi showed no significant relationship with either response rate or survival in patients with unresectable NSCLC receiving CDDP-based chemotherapy. CONCLUSION: p53 alteration is an independent and significant indicator to predict unfavorable prognosis in patients with unresectable NSCLC.
机译:背景:突变型p53蛋白,p-糖蛋白(P-gp)和谷胱甘肽S-转移酶-pi(GST-pi)在不可切除的非小细胞肺癌(NSCLC)患者中的预后意义尚未确定。材料与方法:我们使用从先前未经治疗的NSCLC患者中获得的经支气管活检标本对p53,P-gp和GST-pi进行了免疫组织化学染色。结果:在检查的45位患者中,有18位(40%)患者的p53免疫染色为阳性。与p53阴性肿瘤患者相比,p53阳性肿瘤患者基于顺铂(CDDP)的化疗的客观缓解率显着降低(22%对59%,p = 0.0143)。 p53阳性肿瘤患者的生存期明显短于p53阴性肿瘤患者(中位生存时间:4.6个月对12.2个月,p = 0.011),这已通过多因素分析得到了证实(p = 0.0243)。然而,在接受基于CDDP化疗的不可切除NSCLC患者中,P-gp和GST-pi与缓解率或生存率均无显着关系。结论:p53改变是预测不可切除NSCLC患者预后不良的独立且重要的指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号